Loratadine Articles
Taro Pharma 2nd qtr sales up 336%
29 July 2002
Tokyo pharma stocks - week to July 8
15 July 2002
S-P's Claritin approved in Japan
15 July 2002
Schering-Plough cuts field force
1 July 2002
Impax and Wyeth in OTC collaboration
1 July 2002
IMPAX gets initial OK for Claritin-D 24-hour
3 June 2002
Stock Commentary - New York
27 May 2002
Tokyo pharma stocks - week to May 6
13 May 2002
Ad firm defends the pharma industry
29 April 2002
Rise in US lawsuits for generic blocking
22 April 2002
Stock Commentary - Europe
18 March 2002
Stock Commentary - New York
18 March 2002
UCB not threatened by Claritin's OTC version
18 March 2002
S-P seeks OTC switch for Claritin in USA
18 March 2002
Stock Commentary - New York
4 March 2002
S-P recalls Claritin-D lots; shares fall on concerns
25 February 2002
US push for generics of "gold-standard" drugs
25 February 2002
S-P's Clarinex gets new indication in USA
18 February 2002
Stock Commentary - New York
18 February 2002
Resend: Clarinex indications extended in USA
18 February 2002
US HHS Sec backs "some" OTC switches
18 February 2002
S-P profits hit by charges
28 January 2002
Strong Q4 revenue rise at Sepracor
28 January 2002
Stock Commentary - New York.
21 January 2002
S-P launches Clarinex antihistamine in USA.
21 January 2002
Merck, S-P file in USA for cholesterol drug
7 January 2002
Schering-Plough predicts profit declines
7 January 2002
Schering-Plough predicts profit declines
24 December 2001
Galapagos Genomics and Euroscreen sign GPCR deal
12 December 2001
Stock Commentary - New York
6 December 2001
Stock Commentary - New York
15 November 2001
Sales flat at Schering-Plough as manufacturing problems persist
23 October 2001
FDA and S-P to make deal on plants?
16 October 2001
Consumer groups sue S-P over Claritin claims
15 August 2001
EU approves S-P's desloratadine for CIU
13 August 2001
Taro files ANDA to challenge S-P's Claritin
6 August 2001
Flat 2nd-qtr sales/EPS at Schering-Plough
25 July 2001
UK MCA seeks GSL switch for eight drugs
5 July 2001
Rite Aid cuts prices for Rx cash buys
27 June 2001
US FDA discusses third-party OTC switch call
25 June 2001
CPMP advises approval of S-P's desloratadine
17 May 2001
Unprecedented US Rx-OTC switch request
1 May 2001
Manufacturing woes hit Schering-Plough
18 April 2001
S-P seeks broader usage for Clarinex
17 April 2001
New world market forecasts from DR
6 April 2001
Singulair effective as allergy treatment
23 March 2001
New world market forecasts from DR
7 March 2001
Schering-Plough tumbles as FDA investigates manufacturing plants
19 February 2001
Schering-Plough EPS increases 14.7%
26 January 2001
Stock Commentary - Tokyo
25 January 2001
Desloratadine cleared in European Union
18 January 2001
Impax and Andrx sued by S-P over Claritin infringement
11 January 2001
IMPAX assault on Claritin bastions
15 December 2000
No decision on S-P's Claritin follow-up
31 October 2000
S-P sales growth driven by Claritin
24 October 2000
Gore slams pharma cos over ad spending
20 October 2000
Schering-Plough sees desloratadine backing
12 October 2000
Stock Commentary New York
5 October 2000
S-P happy with full-year EPS forecast
4 October 2000
Compare US Rx drug prices, consumers told
27 September 2000
Schering-Plough files for desloratadine in CIU
7 September 2000
Waxman-Hatch Act revision next year?
6 September 2000
S-P granted extension on US Claritin patent
17 August 2000
Schering-Plough net income up 16%
26 July 2000
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
